BusinessInovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder CancerBy Nasdaq OMXOct 16, 2017, 11:00 AM UTC
